New Pharmacological Approaches to the Management of Depression: From Theory to Clinical Practice

References

• Kuhn R. The treatment of depressive states with G22355 (im-ipramine hydrochloride). American Journal of Psychiatry 1958; 115: 459–464
   PubMed Web of Science ®Google Scholar
• Garattini S, Samanin R. Biochemical hypotheses on antidepres-sant drugs: a guide for clinicians or a toy for pharmacologists?. Psychological Medicine 1988; 18: 7–304
   Web of Science ®Google Scholar
• Sulser F. New perspectives on the mode of action of antidepressant drugs. Trends in Pharmacological Sciences 1979; 1: 92–94
   Web of Science ®Google Scholar
• Finberg J PM. Antidepressant drugs and down-regulation of presynaptic receptors. Biochemical Pharmacology 1987; 21: 3557–3562
   Google Scholar
• Brunello N, Barbaccia M L, Chuang D M, Costa E. Down-regulation of -adrenergic receptors following repeated injections of des-methyl imipramine: permissive role of serotonergic axons. Neuropharmacology 1982; 21: 1145–1149
   PubMed Web of Science ®Google Scholar
• Charney D S, Price L H, Heninger G R. Desipramine-yohimbine combination treatment of refractory depression. Implications for the -adrenergic receptor hypothesis of antidepressant action. Archives of General Psychiatry 1986; 43: 1155–1161
   PubMed Web of Science ®Google Scholar
• Wachtel H. Defective second-messenger function in the etiology of endogenous depression; novel therapeutic approaches. New concepts in depression, M Briley, G Fillion. Macmillan Press, London 1988; 277–293
   Google Scholar
• Chuang D M. Neurotransmitter receptors and phosphoinositide turnover. Annual Reviews of Pharmacology and Toxicology 1989; 29: 71–110
   PubMed Web of Science ®Google Scholar
• Sugrue M F. Do antidepressants possess a common mechanism of action?. Biochemical Pharmacology 1983; 32: 1811–1817
   PubMed Web of Science ®Google Scholar
• Leonard B E. Pharmacological effects of serotonin re-uptake inhibitors. Journal of Clinical Psychiatry 1988; 49(Supplement)12–17
   PubMed Web of Science ®Google Scholar
• Lemberger L, Fuller R W, Zerbe R L. Use of specific serotonin uptake inhibitors as antidepressants. Clinical Neuropharmacology 1985; 8: 299–317
   PubMed Web of Science ®Google Scholar
• Burrows G D, McIntyre I M, Judd F K, Norman T R. Clinical effects of serotonin re-uptake inhibitors in the treatment of depressive illness. Journal of Clinical Psychiatry 1988; 49(Supplement)18–22
   PubMed Web of Science ®Google Scholar
• Freeman H. Progress in antidepressant therapy. Fluoxetine: a comprehensive overview. British Journal of Psychiatry 1988; 153(Supplement 3)
   PubMed Web of Science ®Google Scholar
• Silverstone T. Clinical studies of fluoxetine in depression. International Clinical Psychopharmacology 1989; 4(Supplement l)1–119
   Google Scholar
• Wong D T, Bymaster F P, Horng J S, Molloy B B. A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain. 3–(p-trifluoromethyl phenoxy)-N-methyl-3-phenyl propylamine. Journal of Pharmacology and Experimental Therapeutics 1975; 193: 804–811
   PubMed Web of Science ®Google Scholar
• Schmidt M J, Fuller R W, Wong D T. Fluoxetine, a highly selective serotonin re-uptake inhibitor: a review of preclinical studies. British Journal of Psychiatry 1988; 153(Supplement 3)40–46
   Google Scholar
• Hall J. Fluoxetine: Efficacy against placebo and by dose-an overview. British Journal of Psychiatry 1988; 153(Supplement 3)59–63
   Google Scholar
• Stark P, Hardison C D. A review of multicentre controlled studies of fluoxetine vs imipramine and placebo in out-patients with major depressive disorder. Journal of Clinical Psychiatry 1985; 46: 53–58
   PubMed Web of Science ®Google Scholar
• Cooper G L. The safety of Fluoxetine—An update. British Journal of Psychiatry 1988; 153(Supplement3)77–86
   Google Scholar
• Fisch C. Effect of fluoxetine on the electrocardiogram. Journal of Clinical Psychiatry 1985; 46: 42–44
   PubMed Web of Science ®Google Scholar
• Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and L-tryptophan : five case reports. Biological Psychiatry 1986; 21: 1067–1071
   PubMed Web of Science ®Google Scholar
• Benfield P, Ward A. Fluvoxamine: A review of its phar-macodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 1986; 32: 313–334
   PubMed Web of Science ®Google Scholar
• Biziere K, Worms P, Kan J P, Mandel P, Garattini S, Roncucci R. Minaprine, a new drug with antidepressant properties. Drugs under Experimental Clinical Research 1985; XI(12)831–840
   Google Scholar
• Jouvent R, Lancrenon S, Patay M, Biziere K, Widlocher D. A controlled study of minaprine versus placebo in inhibited depressed outpatients. Abstr. International Symposium of the first European Conference “Recent Advances in Psychiatric Treatment”, Vienna, March, 261984
   Google Scholar
• Bohacek N, Ravic M, Biziere K. Minaprine and imipramine in the treatment of major depressive disorders. A comparative double-blind study. Drugs under Experimental Clinical Research 1987; III(7)435–442
   Google Scholar
• Radmayr E, Biziere K, Bentel U. Comparative effects of minaprine and maprotiline in depressed inhibited patients. A double-blind study. Abstr. International Symposium at The First European Conference “Recent Advances in Psychiatric Treatment”, Vienna, March, 261984
   Google Scholar
• Mikus P, Biziere K, Bentel V. Double blind study of minaprine versus nomifensine in patients with masked depression. Abstr. International Symposium at the first Euorpean Conference “Recent Advances in Psychiatric Treatment”, Vienna, March, 261984
   Google Scholar
• Wheatley D. Minaprine: an anticholinergic free antidepressant?. British Journal of Psychiatry 1989; 155: 106–107
   PubMed Web of Science ®Google Scholar
• Da Prada M, Keller H H, Kettler R, Schaffner R, Pieri M, Burkard W P, Korn A, Haefely W E. RO 11–1163, a specific and short-acting MAO inhibitor with antidepressant properties. Monoamine Oxidase: Basic and Clinical Frontiers, E Kamijo, Usdin, T Nagatsu. Excerpta Medica, Amsterdam 1981; 183–196
   Google Scholar
• Keller H H, Kettler R, Keller G, Da Prada M. Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and RO 16–6491. Naunyn-Schmiedeberg's Archives of Pharmacology 1987; 335: 12–20, (1987)
   PubMed Web of Science ®Google Scholar
• Da Prada M, Kettler R, Burkard W P, Haefley W E. Moclobemide, an antidepressant with short-acting MAO-A inhibition: brain catecholamines and tyramine pressor effects in rats. Monamine oxidase and disease: prospects for therapy with reversible inhibitors, K F Tipton, P. Dostert, M Strolin-Benedetti. Academic Press, London 1984; 137–154
   Google Scholar
• Da Prada M, Kettler R, Keller H H, et al. Neurochemical profile of moclobemide, a short acting and reversible inhibitor of monoamine oxidase type A. Journal of Pharmacology and Experimental Therapeutics 1989; 248: 400–414
   PubMed Web of Science ®Google Scholar
• Koulu M., Scheima M, Kaartinen A, et al. (1989) Inhibition of monoamine oxidase by moclobemide: effects of monoamine nietabolism and secretion of anterior pituitary hormones and cortisol in health volunteers. British Journal of Clinical Pharmacology 1989; 27: 243–255
   PubMed Web of Science ®Google Scholar
• Bobon D P, Rossignol P, Lepage-Goffioul G, Adens A, Gilot P, Breulet M. (1980). L'effect antidepressif du RO 11–1163, inhibitor- selectif de la MAO-A. Comptes Rendus 77e Congress Psychiatrie Neurolgie Francais Paris Masson, P Sizaret. 1980; 1281–1286
   Google Scholar
• Stefanis C N, Alevizos B H, Papadimitriou G N. Antidepressant effect of RO 11–1163 a new MAO inhibitor. International Phar-maco-psychiatry 1982; 17: 43–48
   PubMedGoogle Scholar
• Amrein R, Allen S, Vranesci D, Stabl M. Antidepressant drug therapy: associated risks. Journal of Neural Transmission (Supplement) 1988; 26: 73–86
   Google Scholar
• Blackwell B, Marley E, Price J, Taylor D. Hypertensive interactions between monoamine oxidase inhibitors and food-stuffs. British Journal of Psychiatry 1967; 113: 349–365
   PubMed Web of Science ®Google Scholar
• Korn A, Da Prada M, Raffesberg W, Allen S, Gasic S. (1988). Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor. Journal of Neural Transmission (Supplement) 1988; 26: 57–71
   Google Scholar
• Horowitz D, Lovenberg W, Engelman K, Sjoerdsma A. Monoamine oxidase inhibitors. tyramine, and cheese. Journal of the American Medical Association 1964; 188: 1108–10
   PubMed Web of Science ®Google Scholar
• Schmid-Burgk W, Gieschke R, Allen S, Amrein R. Moclobemide, a new reversible monoamine oxidase inhibitor, and tyramine interaction studies. Current Therapeutic Research 1988; 43: 903–917
   Web of Science ®Google Scholar
• Muller T, Gieschke R, Ziegler W H. Blood pressure response to tyramine-enriched meat before and during MAO-inhibition in man: influence of dosage regimen. Journal of Neural Transmission (Supplement) 1988; 26: 105–114
   Google Scholar
• Schwabe U, Miyoke M, Ohga Y, Daly J W. 4–(3-Cyclopen-tyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK62711):a potent inhibitor of adenosine cyclic 3′5-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain. Molecular Pharmacology 1976; 12: 900–910
   PubMed Web of Science ®Google Scholar
• Przegalinski E, Bigajska K. Antidepressant properties of some phosphodiesterase inhibitors. Polish Journal of Pharmacology and Pharmacy 1983; 35: 233–240
   PubMedGoogle Scholar
• Kehr W, Debus G, Neumeister R. Effects of rolipram, a novel antidepressant, on monoamine metabolism in rat brain. Journal of Neural Transmission 1985; 63: 1–12
   PubMed Web of Science ®Google Scholar
• Zeller E, Steif H J, Pflug B, Sastre-y-Hernandez M. Results of a phase 11 study of the antidepressant effect of rolipram. Phar-macopsychiatry 1984; 17: 188–190
   PubMed Web of Science ®Google Scholar
• Dunner D L, Avery D H, Dager S R, Khan A. Rolipram: A placebo controlled trial in outpatients with major depressive disorder. Psychopharmacology 1988; 96(Supplement)246
   Google Scholar
• Rowlands M WD, Silverstone T, Cookson J C. A double-blind placebo-controlled study of rolipram in depressed in-patients. Journal of Psychopharmacology 1989; 3: 169–174
   PubMedGoogle Scholar
• Elliot-Baker S J, Singh B S. What has happened to the new antidepressant drugs. Medical Journal Australia 1990; 152: 150–153
   PubMed Web of Science ®Google Scholar